Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 24 April ...

Natalizumab eventually ended up as Tysabri, Biogen’s drug for multiple sclerosis, Actemra (tocilizumab) went to Roche as a treatment for rheumatoid arthritis, and Entyvio (vedolizumab ...

Background The ASCEND trial did not find benefit of natalizumab during secondary progressive multiple sclerosis compared with placebo; however, its open-label extension suggests this may be obscured ...

The main patents on Tysabri (natalizumab) expired in the US and Europe in February; although, various use patents claim protection until 2027 and are still in dispute. The green light from the FDA ...

Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod. Methods ...